AstraZeneca's India revenue climbs 33% YoY to Rs. 22.76 billion in FY26

While oncology contributed Rs. 16,100.9 million to remain company's largest therapy area, the key highlight was receipt of 11 new regulatory approvals for medicines and indications

Pfizer and FITT IIT Delhi identify 20 health startups under innovation programme

Selected ventures to receive grants and structured intellectual property support to strengthen protection and management of healthcare innovations

Glenmark posts strong FY26 results with 27.5% revenue jump

Fermenta Biotech reports 26% revenue growth in FY26

Alkem Labs posts highest-ever EBITDA in FY26; Q4 revenue rises 14.6%

Strong domestic and international growth, improving product mix, and operational efficiencies drive margin expansion despite exceptional charges impacting quarterly profit

Hikal swings back to profit in Q4 FY26 despite regulatory hit & strategic charges

Hikal’s Q4 profit remained sharply lower year-on-year, falling 71% from Rs. 50.2 crore in Q4 FY25 as the company absorbed regulatory pressures and strategic accounting adjustments

Supriya Lifescience posts 50% revenue growth in Q4 FY26; PAT rises to Rs 74 crore

On a full-year basis, revenue from operations for FY26 grew 18.9 percent year-on-year to Rs 827.87 crore compared to Rs 696.48 crore in FY25

Gandhar Oil posts robust FY26 profit

PAT soars 201%, EBITDA up 88% on strong PHPO demand & margin expansion

Morepen Labs posts strong Q4 FY26 net profit

For the full year, standalone gross revenue crossed Rs. 1,700 crore

Biopharma firms must diversify CDMO partnerships to avoid costly delays: Shilpa Biologicals MD

Madhav Bhutada says overdependence on large CDMOs and delayed engagement can increase development costs by up to 40% and slow clinical progress